Literature DB >> 8960109

Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression.

S Khaldoyanidi1, M Achtnich, R Hehlmann, M Zöller.   

Abstract

In a variety of human tumors, including high grade Non-Hodgkin's lymphoma (hgNHL), a linkage between expression of CD44 variant isoforms (CD44v) and tumor progression has been described. In search of an easily accessible diagnostic parameter, expression of CD44 standard (CD44s) and CD44 variant isoforms (exons v5, v6, v7 and v10) in peripheral blood lymphocytes (PBLs) of patients with hematological malignancies was evaluated by fluorescence activated cell scanning. The analysis of 30 blood samples of healthy donors and patients with non-malignant diseases and of 183 blood samples of patients with malignant hematological disorders revealed that only in patients with malignant disorders did a measurable proportion of PBLs express CD44 variant isoforms, mostly exons v5, v6, v7 and, less frequently, exon v10. Elevated levels of CD44v expression were noted in PBLs of patients with acute and chronic myeloid leukemia (AML: 16%, CML: 25%), Hodgkin's disease (HD: 17%), multiple myeloma (MM: 22%), polycythemia vera (PV: 33%), acute lymphoid leukemia (ALL: 23%) and, most frequently, in PBLs of patients with non-Hodgkin's lymphoma (NHL:54%). CD44v expression was not restricted to the malignant phenotype, but instead was also noted in T cells, B cells and monocytes, preferentially in a subpopulation of large cells. Furthermore, expression of CD44v in PBLs was not linked to the histological grading or clinical staging. There was, however, an inverse correlation with tumor progression, whereas response to therapy was frequently accompanied by upregulation of CD44v. Thus, expression of CD44v in the PBLs of patients with NHL mainly reflected immune responsiveness. Since NHL manifests itself primarily in lymphoid organs, its progression is difficult to follow. Monitoring of CD44v in PBLs could be used as an additional and convenient parameter for surveying the course of disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960109     DOI: 10.1016/s0145-2126(96)00048-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  The role of CD44 in fetal and adult hematopoietic stem cell regulation.

Authors:  Huimin Cao; Shen Y Heazlewood; Brenda Williams; Daniela Cardozo; Julie Nigro; Ana Oteiza; Susan K Nilsson
Journal:  Haematologica       Date:  2015-11-06       Impact factor: 9.941

Review 3.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

4.  High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Authors:  A G Zeimet; M Widschwendter; M Uhl-Steidl; E Müller-Holzner; G Daxenbichler; C Marth; O Dapunt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients.

Authors:  D Masson; M G Denis; P Lustenberger
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

6.  Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.

Authors:  Wei Li; Min Ji; Fei Lu; Yihua Pang; Xin Dong; Jingru Zhang; Peng Li; Jingjing Ye; Shaolei Zang; Daoxin Ma; Chunyan Ji
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.